Login to Your Account

Wilex, Prometheus in Potential $145M Deal for Rencarex

By Cormac Sheridan

Friday, May 6, 2011
Shares in Wilex AG rose almost 20 percent earlier this week on news that the company secured $19 million up front and could bank another $20 million within 12 months as part of a U.S. deal with Prometheus Laboratories Inc. for its Phase III anticancer antibody Rencarex (girentuximab), which is potentially worth more than $145 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription